Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Brändstedt, Jenny ^a,b   Wangefjord, Sakarias ^a,b   Nodin, Björn ^a   Eberhard, Jakob ^a   Jirström, Karin ^a   Manjer, Jonas ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; ESTROGEN; PROGESTERONE; PROTEIN P53; CCND1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; ORAL CONTRACEPTIVE AGENT; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; ORAL CONTRACEPTIVE USE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK REDUCTION; TISSUE MICROARRAY; CHEMISTRY; COLORECTAL NEOPLASMS; ESTROGEN THERAPY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SWEDEN; TIME;

BETA CATENIN; COLORECTAL NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; CYCLIN D1; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901917862     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-371     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010, 102(6):365-367. 10.1093/jnci/djq031, 2841039, 20208016.
3. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999, 106(5):574-582. 10.1016/S0002-9343(99)00063-7, 10335731.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333. 10.1001/jama.288.3.321, 12117397.
5. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004, 350(10):991-1004. 10.1056/NEJMoa032071, 14999111.
6. Delellis Henderson K, Duan L, Sullivan-Halley J, Ma H, Clarke CA, Neuhausen SL, Templeman C, Bernstein L. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol 2010, 171(4):415-425. 10.1093/aje/kwp434, 2842195, 20067917.
7. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288(7):872-881. 10.1001/jama.288.7.872, 12186605.
8. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res 2012, 5(1):19-27. 3348713, 22574233.
9. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012, 2012:509348. 3409552, 22888469.
10. Brabletz T, Jung A, Kirchner T. Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 2002, 441(1):1-11. 10.1007/s00428-002-0642-9, 12111194.
11. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996, 110(3):669-674. 10.1053/gast.1996.v110.pm8608874, 8608874.
12. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990, 249(4971):912-915. 10.1126/science.2144057, 2144057.
13. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995, 9(1):48-55. 10.1038/ng0195-48, 7704024.
14. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011, 60(3):397-411. 10.1136/gut.2010.217182, 3040598, 21036793.
15. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut 2012, 61(9):1299-1305. 10.1136/gutjnl-2011-300719, 3584677, 22027477.
16. Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, Schaffer D, Samowitz WS. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 2001, 61(1):126-130.
17. Wu AH, Siegmund KD, Long TI, Cozen W, Wan P, Tseng CC, Shibata D, Laird PW. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 2010, 31(6):1060-1067. 10.1093/carcin/bgq009, 2878358, 20064828.
18. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980, 65(6):1201-1207.
19. Fernandez E, La Vecchia C, Franceschi S, Braga C, Talamini R, Negri E, Parazzini F. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998, 9(3):295-300. 10.1097/00001648-199805000-00014, 9583422.
20. Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 2007, 18(7):723-733. 10.1007/s10552-007-9015-7, 17549595.
21. Nichols HB, Trentham-Dietz A, Hampton JM, Newcomb PA. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1212-1218. 10.1158/1055-9965.EPI-04-0845, 15894674.
22. Lin J, Zhang SM, Cook NR, Manson JE, Buring JE, Lee IM. Oral contraceptives, reproductive factors, and risk of colorectal cancer among women in a prospective cohort study. Am J Epidemiol 2007, 165(7):794-801. 10.1093/aje/kwk068, 17215381.
23. Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst 1981, 67(1):57-60.
24. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control 1994, 5(4):359-366. 10.1007/BF01804987, 8080948.
25. Levi F, Pasche C, Lucchini F, La Vecchia C. Oral contraceptives and colorectal cancer. Dig Liver Dis 2003, 35(2):85-87. 10.1016/S1590-8658(03)00004-5, 12747625.
26. Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control 2005, 16(8):965-973. 10.1007/s10552-005-4500-3, 16132805.
27. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009, 15(5):489-498. 10.1093/humupd/dmp017, 19414526.
28. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001, 10(6):489-499. 10.1097/00008469-200112000-00003, 11916347.
29. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhlen M, Jirstrom K. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011, 105(5):666-672. 10.1038/bjc.2011.295, 3188928, 21829192.
30. Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K. Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ 2011, 2:10. 10.1186/2042-6410-2-10, 3179695, 21888663.
31. Brandstedt J, Wangefjord S, Nodin B, Gaber A, Manjer J, Jirstrom K. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol Sex Differ 2012, 3(1):23. 10.1186/2042-6410-3-23, 3504577, 23072404.
32. Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlen M, Ericson Lindquist K, Jirstrom K. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer 2012, 106(5):931-938. 10.1038/bjc.2012.34, 3305956, 22333599.
33. Nodin B, Johannesson H, Wangefjord S, OConnor DP, Lindquist KE, Uhlen M, Jirstrom K, Eberhard J. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol 2012, 7:115. 10.1186/1746-1596-7-115, 3523011, 22935204.
34. Wangefjord S, Brandstedt J, Ericson Lindquist K, Nodin B, Jirstrom K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol 2013, 8(1):10. 10.1186/1746-1596-8-10, 3599130, 23337059.
35. Katz MH, Hauck WW. Proportional hazards (Cox) regression. J Gen Intern Med 1993, 8(12):702-711. 10.1007/BF02598295, 8120690.
36. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995, 87(7):517-523. 10.1093/jnci/87.7.517, 7707438.
37. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995, 87(14):1067-1071. 10.1093/jnci/87.14.1067, 7616598.
38. Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 1987, 55(6):687-694. 10.1038/bjc.1987.140, 2002031, 3620314.
39. Chute CG, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Speizer FE. A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 1991, 2(3):201-207. 10.1097/00001648-199105000-00007, 2054402.
40. Simon MS, Chlebowski RT, Wactawski-Wende J, Johnson KC, Muskovitz A, Kato I, Young A, Hubbell FA, Prentice RL. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012, 30(32):3983-3990. 10.1200/JCO.2012.42.7732, 3488271, 23008295.
41. Tsilidis KK, Allen NE, Key TJ, Sanjoaquin MA, Bakken K, Berrino F, Fournier A, Lund E, Overvad K, Olsen A, Olsen A, Tjønneland A, Byrnes G, Chajes V, Rinaldi S, Boutron-Ruault MC, Clavel-Chapelon F, Chang-Claude J, Kaaks R, Bergmann M, Boeing H, Koumantaki Y, Palli D, Pala V, Panico S, Tumino R, Vineis P, Bas Bueno-de-Mesquita H, van Duijnhoven FJ, van Gils CH, Peeters PH, et al. Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011, 128(8):1881-1889. 10.1002/ijc.25504, 20533550.
42. Hoffmeister M, Raum E, Winter J, Chang-Claude J, Brenner H. Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. Br J Cancer 2007, 97(11):1486-1492. 10.1038/sj.bjc.6604066, 2360268, 17987040.
43. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998, 128(9):705-712. 10.7326/0003-4819-128-9-199805010-00001, 9556463.
44. Lin JH, Morikawa T, Chan AT, Kuchiba A, Shima K, Nosho K, Kirkner G, Zhang SM, Manson JE, Giovannucci E, Fuchs CS, Ogino S. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 2012, 72(12):3020-3028. 10.1158/0008-5472.CAN-11-2619, 3377852, 22511578.
45. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007, 67(15):7534-7539. 10.1158/0008-5472.CAN-06-4275, 17671225.
46. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M, Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000, 92(22):1831-1836. 10.1093/jnci/92.22.1831, 11078760.
47. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011, 305(16):1685-1694. 10.1001/jama.2011.513, 3087286, 21521850.
48. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 2002, 187(1-2):77-86.
49. Hsu HH, Cheng SF, Wu CC, Chu CH, Weng YJ, Lin CS, Lee SD, Wu HC, Huang CY, Kuo WW. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 2006, 49(2):110-116.
50. Jin P, Lu XJ, Sheng JQ, Fu L, Meng XM, Wang X, Shi TP, Li SR, Rao J. Estrogen stimulates the expression of mismatch repair gene hMLH1 in colonic epithelial cells. Cancer Prev Res (Phila) 2010, 3(8):910-916. 10.1158/1940-6207.CAPR-09-0228, 20663978.
51. Issa JP. Colon cancer: it's CIN or CIMP. Clin Cancer Res 2008, 14(19):5939-5940. 10.1158/1078-0432.CCR-08-1596, 18829469.
52. Ogino S, Giovannucci E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 2012, 41(4):1072-1074. 10.1093/ije/dys076, 3429874, 22596930.
53. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013, 14(8):16365-16385. 10.3390/ijms140816365, 3759916, 23965959.